BackNeumora Therapeutics Overview

Neumora Therapeutics Operating Income

Neumora Therapeutics's operating income is $-220M.

Get informed when a big investor buys or sells

+ Follow

Quarterly Operating Income

$-52864000.00
↓ 25.48% YoY

As of Mar 31, 2026

Annual Operating Income (TTM)

$-223084000.00
↓ 18.68% YoY

Trailing 12 months ending Mar 31, 2026

Average Operating Income (Comparison Companies)

Operating Income History

Operating Income Comparison

Annual Operating Income Growth Rate (%)

Annual Operating Income Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin

Neumora Therapeutics (NMRA) FAQ

As of the most recent data (March 2026), NMRA shows a operating income of $-220M. That compares with $-270M in the prior-year period — up 18.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NMRA's operating income is now $-220M (was $-270M) — a 18.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Neumora Therapeutics is outperforming or lagging.

Tracking NMRA's operating income over time shows whether Neumora Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $-220M That compares with $-270M in the prior-year period — up 18.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Neumora Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-220M) with ownership activity and broader fundamentals.